Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study

BACKGROUND: The cost-effectiveness of immunisation strategies with a long-acting monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for protecting infants from Respiratory Syncytial Virus (RSV)-associated illness has not been previously determined for Canada. We estim...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoukat, Affan, Abdollahi, Elaheh, Galvani, Alison P., Halperin, Scott A., Langley, Joanne M., Moghadas, Seyed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663690/
https://www.ncbi.nlm.nih.gov/pubmed/38026446
http://dx.doi.org/10.1016/j.lana.2023.100629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663690/
https://www.ncbi.nlm.nih.gov/pubmed/38026446
http://dx.doi.org/10.1016/j.lana.2023.100629

Ejemplares similares